对于异柠檬酸脱氢酶（IDH）突变型胶质瘤患者，我该如何开具和管理IDH抑制剂？
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?
作者信息
Still Megan E H, Moor Rachel S F, Ghiaseddin Ashley P, Leibetseder Annette, Hottinger Andreas F, Berghoff Anna, Leung Denise
机构信息
Department of Neurosurgery, University of Florida, Gainesville, Florida, USA.
Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, Florida, USA.
出版信息
Neurooncol Pract. 2024 Dec 3;12(Suppl 1):i19-i25. doi: 10.1093/nop/npae112. eCollection 2025 Feb.
Abstract
Recent interest has been in using mIDH inhibitors in patients with IDH-mutant gliomas. This review paper summarizes the indications, side effects, recommended dosing, and management for patients on ivosidenib and vorasidenib.
摘要
近期的研究兴趣在于将异柠檬酸脱氢酶（IDH）抑制剂用于携带IDH突变的神经胶质瘤患者。这篇综述文章总结了使用依维替尼和伏立替尼的患者的适应症、副作用、推荐剂量及管理方法。
相似文献
1
How do I prescribe and manage mIDH inhibitors in patients with IDH-mutant glioma?对于异柠檬酸脱氢酶（IDH）突变型胶质瘤患者，我该如何开具和管理IDH抑制剂？
Neurooncol Pract. 2024 Dec 3;12(Suppl 1):i19-i25. doi: 10.1093/nop/npae112. eCollection 2025 Feb.
2
Who will benefit from vorasidenib? Review of data from the literature and open questions.谁将从vorasidenib中获益？文献数据综述与未解决的问题。
Neurooncol Pract. 2024 Nov 14;12(Suppl 1):i6-i18. doi: 10.1093/nop/npae104. eCollection 2025 Feb.
3
Advances in IDH-mutant glioma management: IDH inhibitors, clinical implications of INDIGO trial, and future perspectives.异柠檬酸脱氢酶（IDH）突变型神经胶质瘤治疗进展：IDH抑制剂、INDIGO试验的临床意义及未来展望
Future Oncol. 2025 Jul;21(16):2089-2099. doi: 10.1080/14796694.2025.2511587. Epub 2025 May 27.
4
The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma.伏立西尼在异柠檬酸脱氢酶突变型胶质瘤治疗中的作用。
Neuro Oncol. 2024 Dec 25. doi: 10.1093/neuonc/noae259.
5
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
6
The Role of Mutant IDH Inhibitors in the Treatment of Glioma.异柠檬酸脱氢酶突变体抑制剂在胶质瘤治疗中的作用。
Curr Neurol Neurosci Rep. 2024 Dec;24(12):631-643. doi: 10.1007/s11910-024-01378-3. Epub 2024 Sep 20.
7
Symptom management in isocitrate dehydrogenase mutant glioma.异柠檬酸脱氢酶突变型神经胶质瘤的症状管理
Neurooncol Pract. 2024 Oct 19;12(Suppl 1):i38-i48. doi: 10.1093/nop/npae088. eCollection 2025 Feb.
8
ATRX loss in adult gliomas lacking H3 alterations or IDH mutations, an exceptional situation for exceptional diagnoses: the experience of Sainte-Anne hospital.在缺乏H3改变或异柠檬酸脱氢酶（IDH）突变的成人胶质瘤中ATRX缺失：特殊诊断的特殊情况——圣安妮医院的经验
Acta Neuropathol Commun. 2025 Jun 13;13(1):131. doi: 10.1186/s40478-025-02044-6.
9
Clinical outcome, radiological findings, and genetic features of IDH-mutant brainstem glioma in adults.成人 IDH 突变型脑桥胶质瘤的临床转归、影像学表现和遗传学特征。
Acta Neurochir (Wien). 2024 Jun 12;166(1):263. doi: 10.1007/s00701-024-06154-3.
10
Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma.肿瘤专家委员会在为异柠檬酸脱氢酶突变型神经胶质瘤患者开具异柠檬酸脱氢酶抑制剂时的作用。
Neurooncol Pract. 2024 Dec 4;12(Suppl 1):i29-i37. doi: 10.1093/nop/npae100. eCollection 2025 Feb.
引用本文的文献
1
Targeting of Mutant Isocitrate Dehydrogenase in Glioma: A Systematic Review.胶质瘤中突变异柠檬酸脱氢酶的靶向治疗：一项系统评价
Cancers (Basel). 2025 Aug 12;17(16):2630. doi: 10.3390/cancers17162630.
本文引用的文献
1
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma.异柠檬酸脱氢酶1（IDH1）突变型胶质瘤患者使用非标签用药依维替尼的情况、获取途径及初步结果
Neurooncol Pract. 2023 Oct 14;11(2):199-204. doi: 10.1093/nop/npad068. eCollection 2024 Apr.
2
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.沃拉西尼布治疗 IDH1 或 IDH2 突变型低级别胶质瘤。
N Engl J Med. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4.
3
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.沃拉西尼布和伊沃西尼布治疗 IDH1 突变型低级别胶质瘤：一项随机、围手术期的 1 期临床试验。
Nat Med. 2023 Mar;29(3):615-622. doi: 10.1038/s41591-022-02141-2. Epub 2023 Feb 23.
4
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.奥拉替尼（FT-2102）治疗复发性或难治性 IDH1 突变型神经胶质瘤患者的多中心、开放标签、Ib/II 期研究。
Neuro Oncol. 2023 Jan 5;25(1):146-156. doi: 10.1093/neuonc/noac139.
5
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.美国食品药品监督管理局批准概要：ivosidenib 用于治疗 IDH1 突变的不可切除或转移性、化疗难治性胆管癌患者。
Clin Cancer Res. 2022 Jul 1;28(13):2733-2737. doi: 10.1158/1078-0432.CCR-21-4462.
6
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.沃拉西尼布，一种 IDH1/2 突变体的双重抑制剂，用于复发性或进行性脑胶质瘤；一项首次人体 I 期试验的结果。
Clin Cancer Res. 2021 Aug 15;27(16):4491-4499. doi: 10.1158/1078-0432.CCR-21-0611. Epub 2021 Jun 2.
7
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.突变型异柠檬酸脱氢酶 1 抑制剂伊维替尼联合阿扎胞苷治疗新诊断的急性髓系白血病。
J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29.
8
Ivosidenib in Isocitrate Dehydrogenase 1Mutated Advanced Glioma.ivosidenib 治疗异柠檬酸脱氢酶 1 突变型高级别胶质瘤
J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12.
9
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.ivosidenib 治疗 IDH1 突变、化疗耐药性胆管癌（ClarIDHy）：一项多中心、随机、双盲、安慰剂对照、3 期研究。
Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13.
10
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.美国食品和药物管理局批准概要：ivosidenib 用于携带异柠檬酸脱氢酶-1 突变的复发性或难治性急性髓系白血病。
Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28.
Zotero 插件